Methods of promoting the growth or differentiation of hematopoietic stem or progenitor cells by non-muscle type cofilin

One of the biggest payoffs in biotechnology has been development of therapeutics that modulate the hematopoietic stem cells. For example, agents such as EPO or G-CSF have become block-buster drugs for stimulation of erythropoiesis or granulopoiesis respectively. The current patent teaches a new way to stimulate hematopoiesis through administration of cofilin and...

Cultured skin and method of manufacturing the same

This patent is useful for generation of skin cells and skin-like cells from umbilical cords. Since cord blood is extracted from the cord and the cord is usually disposed of, this patent may be of particular importance. The only disadvantage of this patent is that its 1 issued claim seems to cover only a certain method of culturing the cells in a specific media. A method of culturing...

Neuroprotection and neuroegenisis by administering cyclic prolyl glycine

This invention relates to the discovery of the functions of cyclic Propyl Glycine as a novel antagonist that either blocks the AMPA and/or the NMDA receptors. Since agonism of these receptors is associated with excitotoxic neuronal death, the invention covers the use of cyclic propyl glycine as a neuroprotectant in a variety of settings...

Methods and compositions for the diagnosis and treatment of hematological disorders using 2777

This patent is a demonstration of creative patent writing, with positive results of claim issuance. Essentially, the inventors found a novel gene called 2777 which is significantly expressed in erythroid cells both in vitro and in vivo. 2777 is also expressed in erythroid progenitor (BFU-E) cells and Glycophorin A positive-lo (GPA-lo) cells in vivo. Since 2777 appears at a structural level to...

Methods of using deacetylase inhibitors to promote cell differentiation and regeneration

The use of histone deacetylase inhibitors for inducing new gene expression of genes that are developmentally silenced is a very exciting method of "reactivating" stem cells. For example, the histone deacetylase inhibitor valproic acid is a clinically used agent that stimulates stem cell expansion. The current patent teaches ways...

Prolactin induced increase in neural stem cell numbers

We at StemCellPatents.com believe that the future of stem cell therapy will involve optimization of current therapeutic approaches that are already in clinical trials.  For example, it is known that intravenous administration of mesenchymal stem cells can generate statistically significant improvement in heart function after heart attacks.  It is also...

Combined regulation of neural cell production

This patent teaches ways of treating neurological disease such as Alzheimer's disease, multiple sclerosis (MS), Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease through administration of several compounds that are already in the clinic such as prolactin and EPO. The patent applies to selectively producing neural cells, including neurons...

Recombinant human albumin fusion proteins with long-lasting biological effects

This patent covers novel vectors for generating fusion proteins comprising one or more regions of the human albumin protein. The patent covers specific nucleotide sequences and most notable albumin-G-CSF fusions that have 5 times longer self life as compared to unmodified G-CSF and at least 3 fold longer half life in plasma. This patent is useful for entities seeking the generate...

Poly-Glu,Tyr for neuroprotective therapy

T regulatory cells are generally seen as antiinflammatory cells that are capable of suppressing pathological immune responses.  These cells have been demonstrated to inhibit inflammatory pathologies such as bone resorption and transplant rejection.  

The current patent takes an...